Quantcast
Last updated on April 21, 2014 at 1:20 EDT

Latest Epidermolysis bullosa Stories

2014-04-01 08:28:31

DURHAM, N.C., April 1, 2014 /PRNewswire/ -- Scioderm, Inc. today announced it has completed enrollment of its Phase 2b study (SD-003) to evaluate the safety and efficacy of SD-101, a novel topical therapy for the treatment of blisters and lesions in patients with Epidermolysis Bullosa (EB.) Key points: -- Epidermolysis Bullosa (EB) is a rare, genetic connective tissue disorder that typically manifests at birth or early childhood. -- All forms of EB share the common symptom...

2014-01-22 08:28:52

DURHAM, N.C., Jan. 22, 2014 /PRNewswire/ -- Scioderm, Inc., today announced that the European Commission (EC) has granted orphan drug designation for SD-101 for the treatment of patients with Epidermolysis Bullosa (EB), a group of rare genetic skin diseases. This decision follows a positive opinion adopted by the Committee for Orphan Medicinal Products (COMP), recommending such designation. Epidermolysis Bullosa is a rare genetic connective tissue condition that, in all of its...

2014-01-07 08:30:32

DURHAM, N.C., Jan. 7, 2014 /PRNewswire/ -- Scioderm, Inc., today announced that Dr. Robert Ryan, President and Chief Executive Officer of Scioderm, was invited to present at the 32nd Annual J.P. Morgan Healthcare Conference at 7:30 a.m. Pacific Standard Time (10:30 a.m. EST) on Thursday, January 16, 2014 in the Elizabethan C/D room of the Westin St. Francis hotel. Dr. Ryan will discuss the company's lead investigational therapy, SD-101, currently in late stage clinical development...

2014-01-06 08:26:03

DURHAM, N.C., Jan. 6, 2014 /PRNewswire/ -- Scioderm, Inc. today announced the initiation of a Phase 2B study designed to evaluate the efficacy and safety of SD-101, a novel topical therapy, for the treatment of non-healing wounds in patients with Epidermolysis Bullosa (EB), a rare, genetic connective tissue disorder that typically manifests at birth or early childhood. "People affected by EB suffer skin blisters, chronic wounds, almost constant pain and itching, and scarring," said...

2013-12-27 10:29:35

Stem cell-based gene therapy holds promise for the treatment of devastating genetic skin diseases, but the long-term clinical outcomes of this approach have been unclear. In a study online December 26th in the ISSCR's journal Stem Cell Reports, published by Cell Press, researchers evaluated a patient with a genetic skin disorder known as epidermolysis bullosa (EB) nearly seven years after he had undergone a gene therapy procedure as part of a clinical trial. The study revealed that a small...

2013-12-17 08:28:43

DURHAM, N.C., Dec. 17, 2013 /PRNewswire/ -- Scioderm, Inc., today announced that the Committee for Orphan Medicinal Products (COMP) issued a positive opinion on the application for orphan designation for SD-101 for the treatment of patients with Epidermolysis Bullosa, (EB), a rare orphan pediatric disease. The "Orphan Medicinal Product Designation" is designed to encourage the development of drugs which may provide significant benefit to patients suffering from rare diseases...

2013-12-02 08:30:54

DURHAM, N.C., Dec. 2, 2013 /PRNewswire/ -- Scioderm, Inc. announced the appointment of John Crowley and William Aliski to the company's Board of Directors. As Chairman & CEO of NASDAQ listed Amicus Therapeutics, John brings a significant rare and orphan disease experience to Scioderm, in addition to his in depth transactional and public sector market experience. His personal drive, commitment and overall determination to find cures for rare diseases such as Pompe and Fabry...

2013-10-30 08:31:06

DURHAM, N.C., Oct. 30, 2013 /PRNewswire/ -- Scioderm, Inc. was honored with the Partners in Progress Award from the Dystrophic Epidermolysis Bullosa Research Association of America (DEBRA). The award recognized the company's recent work developing SD-101, which is a topical therapy being developed to treat the severe skin effects seen in patients with inherited Epidermolysis Bullosa (EB), a rare, genetic, connective tissue disorder for which there is no treatment or cure. Dr. Robert...

2013-10-21 08:29:01

DURHAM, N.C., Oct. 21, 2013 /PRNewswire/ -- Scioderm, Inc. announced the appointment of the company's Co-Founder and CEO, Dr. Robert Ryan, to the board of directors of the Dystrophic Epidermolysis Bullosa Research Association of America (DebRA). DebRA, is the only national non-profit group dedicated to funding research and providing services and programs for those with Epidermolysis Bullosa (EB). Scioderm's lead program is an investigational therapy being evaluated for the treatment...

2013-10-14 08:24:33

DURHAM, N.C., Oct. 14, 2013 /PRNewswire/ -- Scioderm, Inc., today announced that Dr. Robert Ryan, president and chief executive officer of Scioderm, will present at the BIO-Europe Conference at 9:30 a.m. CEST on Tuesday, November 5, at the Messe Wien Exhibition and Congress Center in Vienna, Austria. Dr. Ryan will discuss the company's lead investigational therapy, SD-101, currently in clinical development for the treatment of skin blistering and lesions associated with inherited...